Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-27
2006-06-27
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S025000, C536S017400, C536S004100
Reexamination Certificate
active
07067494
ABSTRACT:
This invention provides analogs of eleutherobin and the eleuthesides modified at the C-11 position or comprising an epoxide functionality from C-11 to C-12. C-11 to C-12 is an ideal location for conjugating functional moieties to the eleutherobin pharmacophore without significant loss of antimitotic activity. Moieties that may be conjugated at C-11 include those intended to increase the solubility of the pharmacophore, to facilitate drug formulation, or to facilitate in vivo delivery or targeting.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5420105 (1995-05-01), Gustavson et al.
patent: 5869514 (1999-02-01), Battistini et al.
patent: 5965718 (1999-10-01), Nicolaou et al.
patent: 6051576 (2000-04-01), Ashton et al.
patent: 6087452 (2000-07-01), Stewart et al.
patent: 6127349 (2000-10-01), Chasalow
patent: 6204054 (2001-03-01), Sutton et al.
patent: 6214966 (2001-04-01), Harris
patent: 6380253 (2002-04-01), Das
patent: 2001/0034333 (2001-10-01), Kosak
patent: 2001/0041189 (2001-11-01), Xu
patent: WO 89/11867 (1989-12-01), None
patent: WO 91/12023 (1991-08-01), None
patent: WO 96/14745 (1996-05-01), None
patent: WO 96/20218 (1996-07-01), None
patent: WO 96/36335 (1996-11-01), None
patent: WO 99/15157 (1999-04-01), None
patent: WO 99/21862 (1999-05-01), None
patent: WO 99/29704 (1999-06-01), None
patent: WO 99/59548 (1999-11-01), None
patent: WO 00/64471 (2000-11-01), None
patent: WO 01/15511 (2001-03-01), None
patent: WO 01/28569 (2001-04-01), None
patent: WO 01/38339 (2001-05-01), None
Bayer, FM., “The Shallow-Water Octocorallia of the West Indian Region”,The Hague,1961, Martinus Nighoff, 65, 75-77.
Britton, R., “Synthetic Transformation of Eleutherobin reveal New Features of its Microtubule-Stabilizing Pharmacophore”,Journal of the American Chemical Society,2001, 123(35), 8632-8633, XP002212128.
Brown, L. et al., Transdermal Delivery of Drugs, 1988,Annual Review of Medicine,39, 221-229.
Cinel, B. et al., “Antimitotic Diterpenes fromErythropodium CaribaeorumTest Pharmacophore Models for Microtubule Stabilization”,Organic Letters,2000, 2(3), 257-260, XP-002159667.
Czerwinski, G. et al., “Cytotoxic Agents Directed to Peptide Hormone Receptors: Defining the Requirements for a Successful Drug”,Proc. Natl. Acad. Sci.,1998, 95, 11520-11525.
D'Ambrosio, M. et al., “Sarcodictyin A and Sarcodictyin B, Novel Diterpenoidic Alcohols Esterfied by (E)-N(1)-Methylurocanic Acid.Isolation from the Mediterranean StoloniferSarcodictyon Roseum”,Helv. Chim. Acta.,1987, 70, 2019-2027.
D'Ambrosio, M. et al., “Isolation from the Mediterranean Stoloniferan CoralSarcodictyon Roseumof Sarcodictyin C,D,E, and F, Novel Diterpenoidic Alcohols Esterfied by (E)-or (Z)-N(1)-Methylurocanic Acid. Failure of the Carbon-Skeleton Type as a Classification Criterion”,Helvitca Chimica Acta.,1988, 71, 964-976.
Fenical, W. et al., “Defensive Properties of Secondary Metabolites from the Caribbean Gorgonian CoralErythopodium Caribaeorum”, Marine Ecology Progress Series,1991, 75, 1-8.
Hooper, G.J. et al., “New Diterpenes from the South African Soft CoralEleutherobia Aurea”, J. Nat. Prod.,1997, 60, 889-893.
Iwaski, S., “Studies on Macrocylic Lactone Antibiotics. IX 1) Novel Macrolides from the FungusRhizopus Chinensis:Precursors of Rhizoxin”,Chem Pharm Bull.,1986, 34, 1387-1390.
Ketzinel, S. et al., “Sarcodictyin A and Two Novel Diterpenoid Glycosides, Eleuthosides A and B, from the Soft CoralEleutherobia Aurea”, J. Nat. Prod.,1996, 59, 873-875.
Kiyoto, S. et al., “A New Antitumor Complex, WF-1360, WF-1360A,B,C,D,E and F”,The Journal of Antibiotics,1986, (Tokyo), 39-762-772.
Lindel, T. et al., “Eleutherobin, a New Cytotoxin that Mimics Paclitaxel (Taxol) by Stabilizing Microtubules”,J. Am. Chem Soc.,1997, 119, 8744-8745.
Long, BH. Et al., “Eleutherobin, a Novel Cytotoxic Agent that Induces Tubulin Polymerization, is Similar to Paclitaxel (Taxol®) l”,Cancer Research,1998, 58, 1111-1115.
Nicolaou, K.C. et al., “Total Synthesis of Eleutherobin and Eleuthosides A and B”,J. Am. Chem. Soc.,1998, 120, 8674-8680.
Ojima, I. et al., “A Common Pharmacophore for Cytotoxic Natural Products that Stabilize Microtubules”,Proc. Natl. Acad. Sci.,1999, 96, 4256-4261.
Roberge, M. et al., “Cell-Based Screen for Antimitotic Agents and Identification of Analogues of Rhizoxin, Eleutherobin, and Paclitaxel in Natural Extracts”,Cancer Research,2000, 60(18), 5052-5058.
Stockwell, BR. et al., “High-Throughput Screening of Small Molecules in Miniaturized Mammalian Cell-Based Assays Involving Post-Translational Modifications”,Chemistry and Biology,1999, 6, 71-93.
Vincent, I. et al., “Mitotic Mechanisms in Alzheimer's Disease?”,The Journal of Cell Biology,1996, 132, 413-425.
Andersen Raymond J.
Britton Robert A.
De Silva E. Dilip
Roberge Michel
Nolan Jason M.
Saeed Kamal A.
The University of British Columbia
Woodcock & Washburn LLP
LandOfFree
Antimitotic eleuthesides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antimitotic eleuthesides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimitotic eleuthesides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638973